Click here to read the articles and download the PDF

Pharmaceutical Commerce - December 2024

Because of the potential for product shortages at pharmacies, the FDA has not only given industry more time for compliance—but time to catch up on boosting the supply chain’s interoperable efforts.

Did Industry Fumble the DSCSA Deadline?

A crash course on the bubble itself, including therapeutic areas most affected.

Going Inside the Gross-to-Net Bubble and Its Nuances

Addressing the bottlenecks in cell and gene therapy manufacturing through a well-designed artificial intelligence approach is essential to avoiding data siloes.

Why AI Advances in CGT Require Getting Data Right

Articles

NK010, which showed promising anti-tumor activity and safety in preclinical studies, will be evaluated in a Phase I clinical trial for ovarian cancer.

FDA Clears Trial of Non-Genetically Modified Natural Killer Cell Therapy

The addressable treatment market for osteopenia is projected to reach more than $30 billion in the United States and $100 billion globally.

Osteoboost Device Gains FDA Clearance to Treat Osteopenia in Postmenopausal Women

Acquisition is expected to strengthen company’s CDMO business, while establishing a footprint in the generics space.

Bora Pharmaceuticals Completes $210 Million Purchase of Upsher-Smith 

Phase Ib study evaluated satri-cel in patients with advanced gastric/gastroesophageal cancer or pancreatic cancer who had progressed on or were intolerant of prior systemic therapy.

Satri-Cel CAR T-Cell Therapy Shows Promising Safety, Efficacy in Gastric, Pancreatic Cancer

Opdivo (nivolumab) with Yervoy (ipilimumab) showed a 79% drop in the risk of disease progression or death compared to chemotherapy in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer.

Opdivo Plus Yervoy Shows Significantly Improved Progression-Free Survival in Metastatic Colorectal Cancer 

A discussion of where cell and gene therapies are currently doing, what's on the horizon, personalization, and much more. 

Cell and Gene Therapy Outlook: Q&A with Fran Gregory, VP of Emerging Therapies, Cardinal Health

Sandoz will buy Cimerli (ranibizumab-eqrn), an interchangeable biosimilar to Lucentis (ranibizumab), for an upfront cash payment of $170 million.

Sandoz, Coherus BioSciences Reach Agreement on Sale of Lucentis Biosimilar

Today's approval amends the accelerated approval granted by the FDA in April 2019 to Balversa (erdafitinib) for patients with metastatic urothelial carcinoma with susceptible FGFR2 or FGFR3 alterations following prior treatment with platinum-containing chemotherapy.

Balversa Gets Full FDA Approval for Locally Advanced, Metastatic Urothelial Carcinoma 

Experts explore ways in which the financial sector refined the healthcare landscape, including its evolutions throughout the years.

How Financialization Has Impacted the US Healthcare System

Videos

In an interview with Pharma Commerce editor Nicholas Saraceno, Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses the changing role of PBMs and recent price structure overhauls.

Featured Content

Pharmaceutical Commerce - December 2024

Did Industry Fumble the DSCSA Deadline?

Going Inside the Gross-to-Net Bubble and Its Nuances

Why AI Advances in CGT Require Getting Data Right